Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Rossari Biotech Ltd

NSE: ROSSARI · BSE: 543213 · Chemicals & Petrochemicals · 37 announcements

Share price
₹422.90
Market cap
₹2,343 Cr
Revenue (annual)
₹2,396 Cr
Net profit (annual)
₹149.2 Cr
P/E (TTM)
15.5×Sector 36.8×
Promoter holding
68.14%-0.01% QoQ
FII holding
2.03%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

22:42 IST NSE
Management Change

Rossari Biotech Management Change

Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.

21:48 IST NSE
Management Change

Rossari Biotech Management Change

Rossari Biotech has re-appointed Ms. Esha Padmanabhan Achan as an Independent Director for a three-year term. Her extensive finance and strategic planning experience strengthens board oversight.

Execution
36 months
21:07 IST NSE
Management Change

Rossari Biotech Management Change

Rossari Biotech Limited announced that Ms. Aparna Sharma completed her tenure as Non-Executive Independent Director effective April 28, 2026. This is a routine board transition following the completion of an appointed term.

20:40 IST NSE
Management Change

Rossari Biotech Management Change

Rossari Biotech Limited announced that Ms. Aparna Sharma (DIN: 07132341) completed her tenure as an Independent Director on April 28, 2026. Consequently, she ceased to be a director and committee member from the end of that day. The board expressed appreciation for her contributions during her association with the company.

20:29 IST NSE
Management Change

Rossari Biotech Management Change

Rossari Biotech Limited has appointed Mr. Udeypaul Singh Gill as a Non-Executive Independent Director for a 36-month term effective April 28, 2026. Mr. Gill brings over forty years of experience in chemicals, textiles, and sustainability. The appointment follows a board meeting outcome to strengthen the company's strategic leadership.

Execution
36 months